The goal of The Optical Probe and Imaging for Cell Functions Platform is to encourage collaborative research effort to develop biochemical-, cell-, and high-content based assays and training amenable to high-throughput screening of chemical compounds or small molecule libraries on live cells. One of the core missions of the Optical Probe and Imaging Platform is the custom development of new fluorescent probes and fluorescence-based biological assays including:
·Characterization and quantification of fluorescent probe absorption spectra, extending into the increasingly-important near-infrared range (NIR).
·Characterization of fluorescent probe steady-state emission into the NIR.
·Quantification of fluorescent probes lifetimes into the NIR, allowing the development of lifetime-based assays to complement intensity-based assays.
·Development of protein- and membrane-binding assays with individual proteins, micelles, or whole cells, based on fluorescence anisotropy.
Another core mission is high-content screening (HCS). The development of fluorescent probes and cell-based assays allows us to perform high-content screening (HCS) in cell-based systems using living cells as tools in biological research to elucidate the cell signaling pathways and functions of normal and diseased cells. HCS can also be used to discover and optimizes new drug candidates. High content screening is a combination of modern cell biology, with all its molecular tools, with automated high resolution microscopy and robotic handling.
High Content Screening System can provide:
·Ultra-fast image acquisition and powerful data processing capabilities translate into immediate results
·Exceptional image quality even at highest speed for more reliable data and more confidence.
·Supports the complete spectrum of HCS applications, from the simplest to the most sophisticated. Tailor a system that's exactly right for the needs of each lab, and easily reconfigure to meet changing requirements.
Rapid online image data processing and thoroughly flexible analysis for all high content cellular applications, including multi-parametric multiplex assays.
The research area of the Du group involves investigation of hypervalent iodine (III) – mediated transformations, including oxidative coupling, rearrangement, cascade reactions, and asymmetric reactions. Additionally, the group develops metal-free methodology for the constructionof heterocyclic compounds and pharmaceutical agents.
The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting. Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates, c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.
The research of the Huang group encompasses the following main areas:
1) Molecular design (AIDD & Chiral Catalyst/ligand Design)
2) XDC Drug Development and Preparation (Protac/RDC...)
3) New Chemical Space Exploration
The research in the group of Siegel encompasses molecular design, chemical synthesis, and structural analysis, which constitute the three principle components of modern stereochemistry. Robust transmission of structural and stereo-chemical information is fundamental to selective chemical processes such as (bio)molecular recognition, enantioselective reactions, and the assembly of designed materials. Beyond symmetry and molecular bonding, stereochemical investigations draw upon concepts from many disciplines and implement techniques such as synthetic methodology, X-ray crystallography, NMR spectroscopy, and computational theory. Research combines synthetic and physical organic chemistry with an eye toward issues of pharmaceutical, material, and life science.
The research in the group of Srinivasan encompasses two main areas, 1) Developing new reaction methodologies: The research topics under this area include bioorthogonal reactions, late-stage modification of advanced chemical entities, C-H activation, and high-throughput amenable synthesis – aiming at advancing the way organic molecules are made for drug discovery and chemical biology applications. 2) Inhibitor discovery based on fragment-based approaches: Design and synthesis of ‘unconventional’ fragments with rich structural diversity. These fragments will be used as a starting point towards novel inhibitors for unexplored biological targets such as the AurB-INCENP interaction.
The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.
The research in the group of Wang involves the design, synthesis, and biological activity evaluation of new compounds, with focus on industrialization of generic drugs, intermediates, and fine chemicals. Specific areas include 1) Design and synthesis of the Rho kinase inhibitor, 2) Design and synthesis of the PDE4 inhibitor, and 3) Design and synthesis of antihistamine drugs
The research in the group of Zhang is encompassed in the areas of chiral separation and proteomics analysis.
研究方向为药理毒理学，主持国自然面上项目、973计划子课题、天津市科委项目等，近5年作为唯一通讯或最后主通讯以天津大学为第一单位在《Pharmacological Reviews》杂志(IF:18，年均发文量28篇)、《Hepatology》（IF:15, 2篇）、《Nature Communications》(IF:14)、《Journal of Experimental and Clinical Cancer Research》(IF:12)等领域内顶刊发表多篇SCI论文。担任美国毒理学会官方杂志《Toxicological Sciences》副主编、美国生物化学和分子生物学会杂志《Journal of Lipid Research》编委、国内杂志《Medicine Advances》编委等。
The research in the group of Zhao encompasses four main areas, including (1) Stimuli-responsive drug delivery systems; (2) Ferroptosis-targeting nanomedicines; (3) Photo-triggered microtubule inhibitors; (4) Pharmaceutical micelles, biomaterials and nanomaterials.
(1) Development of novel phototherapy molecules for disease treatment
(2) Develop new biological probes to assist disease diagnosis and biological mechanism research
The goal of The Optical Probe and Imaging for Cell Functions Platform is to encourage collaborative research effort to develop biochemical-, cell-, and high-content based assays and training amenable to high-throughput screening of chemical compounds or small molecule libraries on live cells. One of the core missions of the Optical Probe and Imaging Platform is the custom development of new fluorescent probes and fluorescence-based biological assays including:
·Characterization and quantification of fluorescent probe absorption spectra, extending into the increasingly-important near-infrared range (NIR).
·Characterization of fluorescent probe steady-state emission into the NIR.
·Quantification of fluorescent probes lifetimes into the NIR, allowing the development of lifetime-based assays to complement intensity-based assays.
·Development of protein- and membrane-binding assays with individual proteins, micelles, or whole cells, based on fluorescence anisotropy.
Another core mission is high-content screening (HCS). The development of fluorescent probes and cell-based assays allows us to perform high-content screening (HCS) in cell-based systems using living cells as tools in biological research to elucidate the cell signaling pathways and functions of normal and diseased cells. HCS can also be used to discover and optimizes new drug candidates. High content screening is a combination of modern cell biology, with all its molecular tools, with automated high resolution microscopy and robotic handling.
High Content Screening System can provide:
·Ultra-fast image acquisition and powerful data processing capabilities translate into immediate results
·Exceptional image quality even at highest speed for more reliable data and more confidence.
·Supports the complete spectrum of HCS applications, from the simplest to the most sophisticated. Tailor a system that's exactly right for the needs of each lab, and easily reconfigure to meet changing requirements.
Rapid online image data processing and thoroughly flexible analysis for all high content cellular applications, including multi-parametric multiplex assays.
The research area of the Du group involves investigation of hypervalent iodine (III) – mediated transformations, including oxidative coupling, rearrangement, cascade reactions, and asymmetric reactions. Additionally, the group develops metal-free methodology for the constructionof heterocyclic compounds and pharmaceutical agents.
The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting. Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates, c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.
The research of the Huang group encompasses the following main areas:
1) Molecular design (AIDD & Chiral Catalyst/ligand Design)
2) XDC Drug Development and Preparation (Protac/RDC...)
3) New Chemical Space Exploration
The research in the group of Siegel encompasses molecular design, chemical synthesis, and structural analysis, which constitute the three principle components of modern stereochemistry. Robust transmission of structural and stereo-chemical information is fundamental to selective chemical processes such as (bio)molecular recognition, enantioselective reactions, and the assembly of designed materials. Beyond symmetry and molecular bonding, stereochemical investigations draw upon concepts from many disciplines and implement techniques such as synthetic methodology, X-ray crystallography, NMR spectroscopy, and computational theory. Research combines synthetic and physical organic chemistry with an eye toward issues of pharmaceutical, material, and life science.
The research in the group of Srinivasan encompasses two main areas, 1) Developing new reaction methodologies: The research topics under this area include bioorthogonal reactions, late-stage modification of advanced chemical entities, C-H activation, and high-throughput amenable synthesis – aiming at advancing the way organic molecules are made for drug discovery and chemical biology applications. 2) Inhibitor discovery based on fragment-based approaches: Design and synthesis of ‘unconventional’ fragments with rich structural diversity. These fragments will be used as a starting point towards novel inhibitors for unexplored biological targets such as the AurB-INCENP interaction.
The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.
The research in the group of Wang involves the design, synthesis, and biological activity evaluation of new compounds, with focus on industrialization of generic drugs, intermediates, and fine chemicals. Specific areas include 1) Design and synthesis of the Rho kinase inhibitor, 2) Design and synthesis of the PDE4 inhibitor, and 3) Design and synthesis of antihistamine drugs
The research in the group of Zhang is encompassed in the areas of chiral separation and proteomics analysis.
研究方向为药理毒理学，主持国自然面上项目、973计划子课题、天津市科委项目等，近5年作为唯一通讯或最后主通讯以天津大学为第一单位在《Pharmacological Reviews》杂志(IF:18，年均发文量28篇)、《Hepatology》（IF:15, 2篇）、《Nature Communications》(IF:14)、《Journal of Experimental and Clinical Cancer Research》(IF:12)等领域内顶刊发表多篇SCI论文。担任美国毒理学会官方杂志《Toxicological Sciences》副主编、美国生物化学和分子生物学会杂志《Journal of Lipid Research》编委、国内杂志《Medicine Advances》编委等。
The research in the group of Zhao encompasses four main areas, including (1) Stimuli-responsive drug delivery systems; (2) Ferroptosis-targeting nanomedicines; (3) Photo-triggered microtubule inhibitors; (4) Pharmaceutical micelles, biomaterials and nanomaterials.
(1) Development of novel phototherapy molecules for disease treatment
(2) Develop new biological probes to assist disease diagnosis and biological mechanism research
